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Abstract 
 
Introduction: Diabetic retinopathy (DR) is a major cause of blindness, so the impact on health related quality of life (HRQL) is 
fundamental to assess the complete burden of this pathology. The present study has the aim of : a) assessing HRQL in diabetic 
patients with diabetic retinopathy through the administration of the SF-12 questionnaire; b)evaluating what is the impact of the 
associated treatments on the HRQL. 
Methods: The study was an observational study carried out using a cross-sectional design in 2017.The patients were recruited in 
the cities of Rome and Palermo in outpatients ambulatories of Diabetology and Ophthalmology. The SF-12 questionnaire was 
administered to calculate two main indicators of HRQL, i.e., Physical composite score (PCS) and Mental composite score (MCS). 
Results: 137 diabetic patients entered the study, 65% males, 65.7% married or cohabitant. The educational level was generally 
low (37.2% with elementary school. The vast majority were patients with type 2 diabetes mellitus, with a median duration of the 
pathology of ten years. 27.7% of the diabetic patients had a retinopathy. Those patients with Diabetic macular edema (DME) (38) 
were treated with Dexamethasone implant (39.5%), Ranibizumab (28.9%), Aflibercept(7.9%), laser (15.8%). Concerning the 
MCS and PCS, respectively, the highest scores are present among males (p = 0.009 and p = 0.007) and highly educated patients (p 
= 0.025 and p = 0.023). No association was found between retinopathy and HRQL scores, both for MCS (p = 0.759) and PCS (p 
= 0.120), even if the highest scores are for patients without retinopathy (43.4 for MCS and 42.1 for PCS). Limiting the analysis to 
patients with DME only, MCS score was found higher in patients treated with Laser and Dexamethasone implant, and lower for 
patients treated with Aflibercepy. However, only patients treated with Dexamethasone implant these results are statistically 
significant (Beta= 6.685; p = 0.039). 
Conclusion: This study confirmed that lowest HRQL scores are among patients with retinopathy. Moreover, diabetic patients as a 
whole showed lowest HRQL scores if compared to the general Italian population. Our results shows the longer the diabetes the best 
the HRQL for the MCS score and the worst the PCS scores. Finally, patients with DR treated for retinopathy had highest MCS 
score if treated with laser and Dexamethasone implant, but only for Dexamethasone implant  the results are statistically significant., 
while no association was found between type of treatment for retinopathy and PCS scores. 
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Introduction 
 
   Diabetic retinopathy (DR) is a major cause of 
blindness, so the impact on health related quality of life 
(HRQL) is fundamental to assess the complete burden of 
this pathology.  
 
 
   The impact of diabetic retinopathy on HRQL has been 
assessed by several studies. A review conducted by 
Sharma and coll. demonstrated both a qualitative and a 
quantitative reduction in HRQL in persons with diabetic 
retinopathy [1]. 
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Diabetic's QoL becomes worse when complications start 
to develop or comorbidities coexist. Dominant amongst 
complications, in HRQoL lowering, but not related to 
risk factors (genetic, the weight of birth, or others) is 
coronary arterial disease followed by renal failure, 
blindness, and the combination of micro- and macro-
vascular complications and in some studies by sexual 
dysfunction [2]. 
   Generally speaking, the longer the diabetes the worse 
the HRQL [3]. Moreover, the presence of any of the four 
major diabetic complications, i.e cardiovascular disease, 
stroke, end-stage renal disease (ESRD) and sight-
threatening diabetic retinopathy (STDR), is usually 
associated with lower HRQoL [4]. 
Quality of life was significantly lower in diabetics with 
DR when compared with those without DR with 
maximum effect seen on general health, general vision 
and mental health. Quality of life decreased as the 
duration of retinopathy and severity of retinopathy 
increased [5]. 
   Trento et al. demonstrated that diabetic retinopathy 
and vision loss modify the way people perceive their own 
ability to function autonomously [6]. 
There is evidence that visual acuity and the vision related 
quality of life of the patients with diabetic retinopathy 
improved significantly after cataract surgery [7]. 
Moreover, there is evidence that in general, HRQL has 
been improved following interventions for Diabetic 
Retinopathy [8]. 
 
Since the scientific literature in Italy on this issue is 
scarce, the present study has the aim of : 
a) assessing HRQL in diabetic patients with 
diabetic retinopathy through the administration 
of the SF-12 questionnaire; 
b) evaluating what is the impact of the associated 
treatments on the HRQL. 
 
 
Materials and Methods 
 
Setting and populations 
  
   The study was an observational study carried out using 
a cross-sectional design in 2017. 
The patients were recruited in the cities of Rome and 
Palermo in outpatients ambulatories of Diabetology and 
Ophthalmology. 
Diabetic patients with and without retinopathy entered 
the study. 
   The sample populations were comprised of three 
different groups: 
 
 
 
a) Diabetic patients with retinopathy before the 
starting of any treatment for the ocular disease; 
b) Diabetic patients with retinopathy after the 
starting of any treatment for the ocular disease; 
c) Diabetic patients without retinopathy. 
The questionnaire 
To all participants, the following data were collected: 
- Socio-demographic data (age, gender, civil 
status, educational level); 
- Clinical data (type of diabetes, years of disease, 
presence of retinopathy, type of treatment for 
the diabetic retinopathy); 
- Measurement of the HRQL, using the Italian 
version of the SF-12 questionnaire. 
The administration of the SF-12 questionnaire allowed 
us to calculate two main indicators of HRQL, that are: 
 Physical composite score (PCS); 
 Mental composite score (MCS). 
Statistical analysis 
   The statistical analysis was carried out using the SPSS 
statistical software, release 23.0. Frequency tables with 
absolute numbers and percentages were calculated. 
Differences between groups were tested using the chi2 test 
for categorical variables and Mann-Withney and Kruskal-
Wallis tests for quantitative variables. A bivariate analysis 
was carried out for the quantitative variables (age, years of 
diabetes, PCS and MCS). In this case a Pearson 
correlation coefficient was calculated. 
   A linear regression analysis was finally conducted using 
PCS and MCS scores as dependent variables. The results 
are shown as beta coefficients. The goodness of fit was 
assessed using the R2. The statistical significance was set 
at p< 0.05.    
 
 
Results  
 
   In table 1 the characteristics of the patients are shown. 
137 diabetic patients entered the study, 65% males, 
65.7% married or cohabitant. The educational level was 
generally low (37.2% with elementary school and 20.4% 
with junior high school). The vast majority were patients 
with type 2 diabetes mellitus, with a median duration of 
the pathology of ten years. 27.7% of the diabetic patients 
had a retinopathy. 
   The most frequent comorbidities were hypertension 
(41.6%) and hyperlipidemia (40.1%). Those patients 
with Diabetic macular edema (DME) (38) were treated 
with Dexamethasone implant (39.5%), Ranibizumab 
(28.9%), Aflibercept(7.9%), laser (15.8%), while 21.1% 
received no treatment. These treatments have been used 
according to the summary of product characteristics 
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             Table 1 – Characteristics of the diabetic patients 
 
Variable    n (%) or median (range) 
Age (Median) 65 (42 - 87) 
Gender 
Females 
Males  
 
48 (35) 
89 (65) 
Civil Status 
Married/Cohabitant 
Divorced 
Widowed 
Single 
 
90 (65.7) 
25 (18.2) 
10 (7.3) 
12 (8.8) 
Educational Level 
Elementary 
Junior High School 
Senior High School 
University 
 
51 (37.2) 
38 (20.4) 
28 (20.4) 
20 (14.6) 
Type Of Diabetes 
Type 1  
Type 2 
 
4 (2.9) 
133 (97.1) 
Years Of Diabetes (Median. Range) 10 (1 – 50) 
Retinopathy 
Yes- 
No 
 
38 (27.7) 
99 (72.3) 
Other Pathologies 
Hypertension 
Hyperlipidemia 
Obesity  
 
57 (41.6) 
55 (40.1) 
36 (26.3) 
Type Of Treatment For Diabetic Macular Edema
None 
Laser 
Dexamethasone Implant 
Ranibizumab 
Aflibercept  
Pegaptanib Sodium 
 
8 (21.1) 
6(15.8) 
15 (39.5) 
11 (28.9) 
3 (7.9) 
0 (0) 
 
 
 
  In  table 2 the univariate and bivaiate analyses are 
shown. Concerning the first score, there is an association 
between MCS and gender as well as educational level. 
The highest scores are present among males (p = 0.009) 
and highly educated patients (47.8 for patients with 
junior high school and 44.7 for patients with a degree, p 
= 0.025).  
   The same pattern is shown as far as concerns PCS, with 
the highest scores among males (p = 0.007) and patients 
with a university degree (p = 0.023). there is no 
association between retinopathy and health-related 
quality of life scores, both for MCS (p = 0.759) and PCS 
 
 
 
 
 
(p = 0.120), even if the highest scores are for patients 
without retinopathy (43.4 for MCS and 42.1 for PCS). 
In relation to the bivariate analysis, no correlation was 
found between age and years of diabetes with the  health-
related quality of life scores. 
   Considering the treatment for retinopathy, no 
association was found with MCS (p = 0.189) and PCS (p 
= 0.489). In the first case the highest score for the 
pharmacological treatment was found for the patients 
treated with Dexamethasone implant (MCS = 42.8), 
while for PCS the highest score was for diabetic patients 
treated with Aflibercept (median = 45.1). 
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Table 2 – Results of the univariate and bivariate analyses: Dependent variables PCS and MCS 
 
Variable    MCS p PCS P 
Age * 0.012 0.894 -0.136 0.116
Gender 
Females 
Males  
 
39.0 (18.1 – 62.5) 
46.2 (13.9 – 61.4) 
0.009 37.2 (18.5- 59.3) 
42.8 (18.1 – 65.2) 
 
0.007 
Civil Status 
Married/Cohabitant 
Divorced 
Widowed 
Single 
 
41.4 (18-9 – 62.5) 
40.8 (18.1 – 61.4) 
51.4 (27.6 – 61.2) 
46.2 (13.9 – 56.7) 
 
0.272 
40.0 (18.1 – 65.2) 
47.1 (25.4 – 58.8) 
45.0 (26 – 53.8) 
41.2 (20.2 - 57) 
 
 
0.396 
Educational Level 
Elementary  
Junior High School 
Senior High School 
University 
 
40 (18.1 – 53.8) 
39.3 (13.9 – 61.2) 
47.8 (18.9 – 62.5) 
44.7 (26.1 – 57.9) 
 
0.025 
39.1 (23 - 57) 
39 (18.1 – 65.2) 
42.4 (25.8 – 55.6) 
49.9 (20.2 -59) 
 
 
0.023 
Type of diabetes 
Type 1  
Type 2 
 
45.5 (26.5 – 54.5) 
42.4 (13.9 – 62 .5) 
0.744 42.7 (32.3  50.5) 
41.1 (18.1 – 65.2) 
 
0.958 
Years of diabetes * 0.039 0.658 -0.019 0.825
Retinopathy 
Yes 
No 
 
40.4 (18.1 – 61.4) 
43.4 (13.9 – 62.5) 
0.759 39.4 (18.1 – 55.1) 
42.1 (18.5 – 65.2) 
 
0.120 
Other Pathologies 
Hypertension 
Hyperlipidemia 
Obesity  
 
43.6 (18.9 – 61.4) 
40.3 (18.9 – 61.2) 
44.4 (19.8 – 57.8) 
0.369 
0.304 
0.591 
39.9 (18.5 – 57.1) 
38.8 (20.8 – 57.1) 
45.4 (18.5 – 58.8) 
 
0.369 
0.098 
0.366 
Type of treatment for diabetic 
retinopathy 
None 
Laser 
Dexamethasone implant 
Ranibizumab 
Aflibercept 
 
 
48.9 (35 – 51.9) 
51.4 (36.8 – 61.4) 
42.8 (28.7 – 55.8) 
36.7 (19.8 – 56.1) 
36.1 (26.5 – 38.8) 
 
 
0.189 
 
34.3 (31.9 – 46.9) 
47.6 (37.6 – 48.3) 
38.3 (25.8 – 55.1) 
39 (18.1 – 46.3) 
45.1 (34.5 – 46.3) 
 
 
 
0.489 
 *correlation coefficient 
 
 
 
 
 
 
 
   In  table 3 the results of the multivariate analyses are 
shown. As far as concerns MCS, the mental score is 
significantly influenced by gender (lower score for 
females: Beta=-3.935; p = 0.047) and educational level 
(highest score for higher education Beta= 5-165; p = 
0.012). On the other hand, in relation to PCS, a similar 
pattern is shown.  
 
   The physical score is influenced by gender (lower score 
for females: Beta=-4.515; p = 0.047) and educational 
level (highest score for higher education Beta= 3.964; p = 
0.072). In both models, diabetic patients with 
retinopathy have lower MCS and PCS scores, but these 
differences are not statistically significant. 
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Table 3 – Results of the multivariate analyses: Dependent variables PCS and MCS 
 
Variable    MCS
Beta 
p PCS
Beta 
p 
Age  0.122 0.255 0.010 0.936
Gender 
Females -3.935 0.047 -4.515 
 
0.035 
Civil status 
Married/cohabitant -0.593 0.764 -2.305 
 
0.301 
Educational Level 
Senior High School/University 5.165 0.012 3.964 
 
0.072 
Type Of Diabetes 
Type 2 -2.179 0.686 -2.562 
 
0.673 
Years of diabetes (median) 0.033 0.812 0.041 0.793
Retinopathy  
Yes -1.644 0.537 -3.044 
 
0.305 
Other Pathologies 
Hypertension 
Hyperlipidemia 
Obesity  
1.792 
-2.566 
-0.060 
0.365 
0.189 
0.979 
-1.086 
-2.933 
0.712 
 
0.610 
0.164 
0.769 
 
 
 
   Limiting the analysis to patients with retinopathy only 
(Table 4), and taking patients treated with Ranibizumab 
as a reference, MCS score was found higher in patients 
treated with Laser and Dexamethasone implant, and 
lower for patients treated with Aflibercepy. However, 
only patients treated with Dexamethasone implant these 
results are statistically significant (Beta= 6.685; p = 
0.039). 
   On the other hand, for the PCS, the physical score is 
higher in patients treated with Laser, Dexamethasone 
implant and Aflibercepy, but these differences are not 
significant. 
 
 
 
 
Table 4 - Results of the multivariate analyses including only patients with retinopathy: Dependent variables PCS and MCS  
 
Variable    MCS
Beta* 
p PCS 
Beta* 
p
Type of treatment  
Ranibizumab (reference) 
Laser 
Dexamethasone implant 
Aflibercepy  
 
11.054 
6.668 
-4.552 
 
 
0.059 
0.039 
0.439 
 
 
5.810 
0.613 
6.110 
 
0.340 
0.847 
0.289 
*Linear regression analysis adjusted for age, gender, years of diabetes, educational level, civil status  
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Discussion
 
   This study took in consideration almost 140 patients 
with diabetes mellitus, and one fourth of them had a 
DME. As far as we know, this is the first study conducted 
in Italy that measured the HRQL in patients with DR. 
As seen in previous studies [1,9,10], we found lowest 
HRQL scores among patients with retinopathy, even if in 
a non-significant way. The diabetic patients as a whole 
showed lowest HRQL scores if compared to the general 
Italian population [11]. 
Our results are partially in contrast with those of 
Schanner and coll [3], concerning the correlation 
between the duration of the diabetes and the HRQL 
scores. In our sample the longer the diabetes the best the 
HRQL for the MCS score and the longer the diabetes the 
worst the PCS scores. 
The study also shows that patients with DR treated for 
retinopathy had highest MCS score if treated with laser 
and Dexamethasone implant, but only for 
Dexamethasone implant  the results are statistically 
significant.  
   No association was found between type of treatment 
for retinopathy and PCS scores. 
The present study suffers from some limitations. First of 
all this is a cross-sectional study and the association 
between the variables investigated and HRQL scores was 
checked only once. Moreover, some of the variables taken 
into consideration were self-reported by the patients and 
there was no possibility for checking for completeness 
and correctness. In future studies, it will be wise to collect 
data prospectively in order to see differences in time of 
the HRQL scores in patients with DR, both for all 
patients and for patients treated with different type of 
drugs.  
   In terms of strengths of the study, the sample was 
drawn from two Italian regions. Moreover, multivariate 
analyses were performed so that the results were adjusted 
for possible confounders.  
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